Reduced progression of atherosclerosis in apolipoprotein E-deficient mice treated with lacidipine is associated with a decreased susceptibility of low-density lipoprotein to oxidation

International Journal of Experimental Pathology

Volumn 85, Issue 2, 2004, Pages 105-114

  Cristofori, Patrizia ^a   Crivellente, Federica ^a   Campagnola, Mario ^b   Pasini, Anna Fratta ^b   Garbin, Ulisse ^b   Rigoni, Anna ^b   Tosetti, Maria ^b   Turton, John ^c   Faustinelli, Ivo ^a   Cominacini, Luciano ^b  

^a GSK   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antioxidant; Apo E deficient mice; Atherosclerosis; Dihydropiridine; High fat diet; Lacidipine; Oxidized LDL

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CALCIUM ANTAGONIST; LACIDIPINE; LIPID; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA ATHEROSCLEROSIS; AREA UNDER THE CURVE; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE RESISTANCE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 3; LIPID ANALYSIS; LIPID OXIDATION; LIPID PEROXIDATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN; VITAMIN BLOOD LEVEL;

ANIMALS; ANTIOXIDANTS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DISEASE SUSCEPTIBILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALONDIALDEHYDE; MICE; MICE, KNOCKOUT; RANDOM ALLOCATION; VITAMIN E;

EID: 2542558107     PISSN: 09599673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0959-9673.2004.00375.x     Document Type: Article

References (49)

1. van Amsterdam F.T.M., Roveri A., Maiorino M., Ratti E., Ursini F. (1992) Lacidipine: a dihydropyridine calcium antagonist with antioxidant activity. Free Radic. Biol. Med. 12, 183-187.
2. Avogaro P., Bittolo Bon G., Cazzolato G. (1988) Presence of a modified low density lipoprotein in humans. Atherosclerosis 8, 79-87.
3. Babiy A.V., Gebicky J.M., Sullivan D.R. (1992) Increased oxidazibility of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation. Biochem. Pharmacol. 43, 995-1000.
4. Boyd H.C., Gown A.M., Wolfbauer G., Chait A. (1989) Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am. J. Pathol. 135, 815-824.
5. Breslow J. (1993) Transgenic mouse models of lipoprotein metabolism and atherosclerosis. Proc. Natl. Acad. Sci. USA 90, 8314-8318.
6. Bruckdorfer K.R. (1993) Non-enzymatic oxidation of lipids lipoproteins: the role of metals and nitric oxide. Curr. Opin. Lipidol. 4, 238-243.
7. Carbonneau M.A., Peuchant E., Sess D., Canioni P., Clerc M. (1991) Free and bound malonyldialdehyde measured as thiobarbituric acid adduct by HPLC. Clin. Chem. 37, 1423-1429.
8. Cathcart M.A., McNally A.K., Chisholm G.M. (1991) Lipoxygenase-mediated transformation of human low density lipoprotein to an oxidized cytotoxic complex. J. Lipid Res. 32, 63-70.
9. Cathcart M.A., McNally A.K., Morel D.W., Chisholm G.M. (1989) Superoxide anion participation in human monocyte-mediated oxidation of low-density lipoprotein to a cytotoxin. J. Immunol. 142, 1963-1969.
10. Chamulitrat W., Hughes M.F., Eling T.E., Mason R.P. (1991) Superoxide and peroxy radical generation from the reduction of polynsaturated fatty acid hydroperoxides by sobean lipoxygenase. Arch. Biochem. Biophys. 290, 153-159.
11. Cominacini L., Garbin U., Cenci B. et al. (1991b) Predisposition to LDL oxidation during copper-catalyzed oxidative modification and its relation to alpha-tocopherol content in humans. Clin. Chim. Acta. 204, 57-68.
12. Cominacini L., Garbin U., Davoli A. et al. (1991a) A simple test for predisposition to LDL oxidation based on the fluorescence development during copper-catalyzed oxidative modification. J. Lipid Res. 32, 349-358.
13. Cominacini L., Garbin U., De Santis A., Campagnola M., Davoli A., Fratta Pasini A. (1996) Mechanisms involved in the in vitro modification of low density lipoprotein by human umbilical vein endothelial cells and copper ions. J. Lipid Med. 13, 19-33.
14. Cominacini L., Garbin U., Fratta Pasini A. et al. (1997a) Antioxidants inhibit the expression of intracellular cell adhesion molecole-1 and vascular cell adhesion molecole-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Radic. Biol. 22, 117-127.
15. Cominacini L., Garbin U., Fratta Pasini A. et al. (1998) Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: inhibitory effect of lacidipine. J. Hypertens. 16, 1913-1919.
16. Cominacini L., Garbin U., Pastorino A.M. et al. (1997b) Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells. Diabetologia 40, 165-172.
17. Cominacini L., Garbin U., Pastorino A.M. et al. (1993) Predisposition to LDL oxidation in patients with and without angiographically established coronary artery disease. Atherosclerosis 99, 63-70.
18. Cominacini L., Garbin U., Pastorino A.M. et al. (1994a) Increased susceptibility of LDL to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Diabetes Res. 26, 173-184.
19. Cominacini L., Pastorino A.M., Garbin U. et al. (1994b) The susceptibility of LDL to in vitro oxidation is increased in hypercholesterolemic patients. Nutrition 10, 527-531.
20. Cristofori P., Lanzoni A., Gaviraghi G., Turton J., Sbarbati A. (2000a) Anti-atherosclerotic activity of the calcium antagonist lacidipine in cholesterol-fed hamsters. Biomed. Pharmacother. 54, 93-99.
21. Cristofori P., Lanzoni A., Quartaroli M. et al. (2000b) The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J. Hypertens. 18, 1429-1436.
22. Dieber-Rotheneder M., Puhl H., Waeg G., Striegl G., Esterbauer H. (1991) Effect of oral supplementation with alpha-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. J. Lipid Res. 32, 1325-1332.
23. Esterbauer H., Jugens G., Quehenberger O., Koller E. (1987) Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J. Lipid Res. 28, 495-509.
24. Esterbauer H., Rotheneder M., Striegl G. et al. (1989) Vitamin E and other lipophilic antioxidants protect LDL against oxidation. Fat. Sci. Technol. 91, 16-324.
25. Hayek T., Attias J., Coleman R. et al. (1999) The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, lasortan inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc. Res. 44, 579-587.
26. Hayek T., Attias J., Smith J., Breslow J.L., Keidar S. (1998) Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. J. Cardiovasc. Pharmacol. 31, 540-544.
27. Hayek T., Oiknine J., Brook J.G., Aviram M. (1994) Increased plasma and lipoprotein lipid peroxidation in apo E deficient mice. Biochem. Biophys. Res. Commun. 201, 1567-1574.
28. Mao S.J., Yates M.T., Rechtin A.E., Jackson R.I., Van Sicule W.A. (1991) Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits. J. Med. Chem. 34, 298-302.
29. Maor I., Hayek T., Coleman R., Aviram M. (1997) Plasma LDL oxidation leads to its aggregation in the atherosclerotic apo E deficient mouse. Arterioscler. Thromb. Vasc. Biol. 17, 2995-3005.
30. Nakashima Y., Plump A.S., Raine E.W., Brelow J., Ross R. (1994) ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the aortic tree. Arterioscler. Thromb. 14, 133-140.
31. Napoli C., Salomone S., Godfraind T. et al. (1999) 1,4-dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats. Stroke 30, 1907-1915.
32. Niki E. (1987) Antioxidants in relation to lipid peroxidation. Chem. Phys. Lipids 44, 227-253.
33. Piedrahita J.A., Zhang S.H., Hagaman J.R., Oliver P.M. (1992) Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. USA 89, 4471-4475.
34. Reddick R.I., Zhang S.H., Maeda N. (1994) Atherosclerosis in mice lacking apoE: evaluation of lesional development and progression. J. Atheroscler. Thromb. 14, 141-147.
35. Regnstrom J.N., Nilsson J., Tornavall P., Landou C., Hamsten A. (1992) Susceptibility to low density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 339, 1183-1186.
36. Rojstaczer N. & Triggle D.J. (1996) Structure-function relationships of calcium antagonists. Effect on oxidative modification of low density lipoprotein. Biochem. Pharmacol. 51, 141-150.
37. Rosenfeld M.E. (1991) Oxidized LDL affects multiple atherogenic cellular responses. Circulation 83, 2137-2140.
38. Sasahara M., Raines E.W., Chait A. et al. (1994) Inhibition of hypercolesterolemia-induced atherosclerosis in the nonhuman primate by probucol. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J. Clin. Invest. 94, 155-164.
39. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A., Gartner F.H., Provenzano A.C. (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem. 105, 293-299.
40. Sobal G., Menzel E.J., Sinzinger H. (2001) Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation. Biochem. Pharmacol. 61, 373-379.
41. Steinberg D. (1997) Oxidative modification of LDL and atherogenesis. Circulation 95, 1062-1071.
42. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. (1989) Beyond cholesterol. Modification of low-density lipoprotein that increases its atherogenicity. M. Engl. J. Med. 320, 915-924.
43. Tangirala R.K., Casanada F., Miller E., Witztum J., Steinberg D., Palinski W. (1995b) Effect of the antioxidant N,N′-diphenylenediamine (DPPD) on atherosclerosis in apo E deficent mice. Arteriosder. Thromb. Vasc. Biol. 15, 1625-1630.
44. Tangirala R.K., Rubin E.M., Palinski W. (1995a) Quantitation of atherosclerosis in marine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid Res. 36, 2320-2328.
45. Thomas S.T., Neuzil J., Mohr D., Stocker R. (1995) Coantioxidants make alpha-tocopherol and efficient antioxidant for low density lipoprotein. Am. J. Clin. Nutr. 62, 1357-1364.
46. Wiklund O., Mattson L., Bjornheden T., Camejo G., Bondjers G. (1991) Uptake and degradation of low density lipoproteins in atherosclerotic rabbit aorta: role of local LDL modification. J. Lipid Res. 32, 55-62.
47. Yoshida Y. & Niki E. (1992) Oxidation of methyl linoleate in acqueous dispersions induced by copper and iron. Arch. Biochem. Biophys. 295, 107-114.
48. Zanchetti A., Gene Bond M., Hennig M. et al. (2002) Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Circulation 106, 2422-2427.
49. Zhang S.H., Reddick R.L., Piedrahita J.A., Maeda N. (1992) Spontaneous hypercolesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258, 468-471.